Hold the device against the skin: the impact of injection duration on user’s force for handheld autoinjectors

References

• Kim H, Park H, Lee SJ. Effective method for drug injection into subcutaneous tissue. Sci Rep. 2017 Aug 29;7(1):9613.
   PubMedGoogle Scholar
• Jones GB, Collins DS, Harrison MW, et al. Subcutaneous drug delivery: an evolving enterprise. Sci Transl Med. 2017 Aug 30;9(405). PubMed PMID: 28855399; eng. DOI:10.1126/scitranslmed.aaf9166.
   Web of Science ®Google Scholar
• Callis Duffin K, Bagel J, Bukhalo M, et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017 Jan;31(1):107–113. PubMed PMID: 27500949.
   PubMed Web of Science ®Google Scholar
• Hudry C, Lebrun A, Moura B, et al. Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis. Rheumatol Ther. 2017 Jun;4(1):183–194. PubMed PMID: 28243967; PubMed Central PMCID: PMC5443726.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Baret-Cormel L, van Hoogstraten H, et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2017 Dec;5. PubMed PMID: 29209946. DOI:10.1007/s40744-017-0090-2.
   PubMed Web of Science ®Google Scholar
• Schiff M, Koo J, Jin E, et al. Usability and acceptability of the abatacept pre-filled autoinjector for the subcutaneous treatment of rheumatoid arthritis. Adv Ther. 2016 Feb;33(2):199–213. PubMed PMID: 26833303; PubMed Central PMCID: PMC4769728.
   PubMed Web of Science ®Google Scholar
• Sheikh SZ, Hammer AE, Fox NL, et al. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus. Int J Clin Pharmacol Ther. 2016 Nov;54(11):914–922. PubMed PMID: 27668697; PubMed Central PMCID: PMC5100660.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Full prescribing information: FASENRA (benralizumab injection, for subcutaneous use; 2019.
   Google Scholar
• GlaxoSmithKline. Full prescribing information: NUCALA (mepolizumab) for injection, for subcutaneous use; 2019.
   Google Scholar
• AMAG. Full prescribing information: VYLEESI (bremelanotide injection), for subcutaneous use; 2019.
   Google Scholar
• Genentech. Full prescribing information: ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use; 2019.
   Google Scholar
• Eli Lilly. Full prescribing information: EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use; 2018.
   Google Scholar
• Amgen. Full prescribing information: AIMOVIG^TM (erenumab-aooe) injection, for subcutaneous use; 2018.
   Google Scholar
• Sanofi-Aventis. Full prescribing information: KEVZARA (sarilumab) injection, for subcutaneous use; 2019.
   Google Scholar
• Eli Lilly. Full prescribing information: TALTZ (ixekizumab) injection, for subcutaneous use; 2019.
   Google Scholar
• GlaxoSmithKline. Full Prescribing Information: BENLYSTA (belimumab) injection, for subcutaneous use. 2019.
   Google Scholar
• Mathaes R, Koulov A, Joerg S, et al. Subcutaneous injection volume of biopharmaceuticals—pushing the boundaries. J Pharm Sci. 2016 Aug 01;105(8):2255–2259.
   PubMed Web of Science ®Google Scholar
• Jain M, Doughty D, Clawson C, et al. Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates. Int J Clin Pharmacol Ther. 2017 Jul;55(7):606–620. PubMed PMID: 28590244; PubMed Central PMCID: PMCPMC5480250. eng.
   PubMed Web of Science ®Google Scholar
• Dias C, Abosaleem B, Crispino C, et al. Tolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjects. AAPS PharmSciTech. 2015 Oct;16(5):1101–1107. PubMed PMID: 25693652; PubMed Central PMCID: PMCPMC4674646. eng.
   PubMed Web of Science ®Google Scholar
• Qin L, Chen S, Flood E, et al. Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-naïve patients with type 2 diabetes mellitus: a multinational preference study. Diab Ther. 2017 April 01;8(2):321–334.
   Google Scholar
• Bolge SC, Goren A, Brown D, et al. Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. Patient Prefer Adherence. 2016;10:1079–1090. PubMed PMID: 27390518.
   PubMed Web of Science ®Google Scholar
• Nguyen H, Posner J, Kalsekar I, et al. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes AU - Hauber, A. Brett. Curr Med Res Opin. 2016 Feb 01;32(2):251–262.
   PubMed Web of Science ®Google Scholar
• Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385–1399. PubMed PMID: 27528802.
   PubMed Web of Science ®Google Scholar
• Berteau C, Filipe-Santos O, Wang T, et al. Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance. Med Devices. 2015;8:473–484. PubMed PMID: 26635489.
   Google Scholar
• Sacha G, Rogers JA, Miller RL. Pre-filled syringes: a review of the history, manufacturing and challenges. Pharm Dev Technol. 2015 Jan 02;20(1):1–11.
   PubMed Web of Science ®Google Scholar
• Lange J, Richard P, Bradley N. Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population. Med Devices (Auckl). 2015;8:255–264. PubMed PMID: 26082667; PubMed Central PMCID: PMC4461121.
   PubMedGoogle Scholar
• Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082–1090. PubMed PMID: 25243910.
   PubMed Web of Science ®Google Scholar
• Schneider A, Kolrep H, Jordi C, et al. How to prevent medication errors: a multidimensional scaling study to investigate the distinguishability between self-injection platform device variants. Expert Opin Drug Deliv. 2019 Aug 03;16(8):883–894.
   PubMed Web of Science ®Google Scholar
• Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–2121.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122. PubMed PMID: 29171818.
   Google Scholar
• Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016 Jan 02;387(10013):40–52.
   PubMed Web of Science ®Google Scholar
• Teva. Full prescribing information: AJOVYTM (fremanezumab-vfrm) injection, for subcutaneous use; 2018.
   Google Scholar
• Regeneron. Full prescribing information: DUPIXENT® (dupilumab) injection, for subcutaneous use; 2018.
   Google Scholar
• Valeant. Full prescribing information: SILIQ™ (brodalumab) injection, for subcutaneous use; 2018.
   Google Scholar
• Novartis. Study of efficacy and safety of secukinumab 2 mL auto-injector (300 mg) in subjects with moderate to severe plaque psoriasis (NCT03589885); 2018 [cited 2019 Feb 02].
   Google Scholar
• Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015 Sept 01;3(9):692–701.
   PubMed Web of Science ®Google Scholar
• Zijlstra E, Jahnke J, Fischer A, et al. Impact of injection speed, volume, and site on pain sensation. J Diabetes Sci Technol. 2018;12(1):163–168. PubMed PMID: 28990437.
   PubMedGoogle Scholar
• Doughty DV, Clawson CZ, Lambert W, et al. Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery. J Pharm Sci. 2016 Jul 01;105(7):2105–2113..
   PubMed Web of Science ®Google Scholar
• Allmendinger A, Mueller R, Schwarb E, et al. Measuring tissue back-pressure – in vivo injection forces during subcutaneous injection. Pharm Res. 2015 Jul;32(7):2229–2240. PubMed PMID: 25537343; eng.
   PubMed Web of Science ®Google Scholar
• Schneider AE, Lange J. Pen devices for self-injection: contrasting measured injection force with users’ perceived ease of injection. Expert Opin Drug Deliv. 2018 Feb 01;15(2):115–125.
   PubMed Web of Science ®Google Scholar
• UPA Association. UPA code of professional conduct for usability practitioners. Bloomingdale (IL): Usability Professionals’ Association; 2005.
   Google Scholar
• EPMR Association. EphMRA 2017 code of Conduct V4.indd. European Pharmaceutical Market Research Association; 2017.
   Google Scholar
• Tischer B, Mehl A. Patients’ and nurses’ preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Preference Adherence. 2018;12:1413.
   PubMed Web of Science ®Google Scholar
• Xiao X, Li W, Clawson C, et al. Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system. Patient Prefer Adherence. 2018:12:515–526. PubMed PMID: 29674844.
   PubMed Web of Science ®Google Scholar
• Barker P, Ferguson GT, Cole J, et al. Single-use autoinjector functionality and reliability for at-home benralizumab administration: GRECO trial results. J Allergy Clin Immunol. 2019;143(2):AB96.
   Web of Science ®Google Scholar
• Bernstein D, Pavord ID, Chapman KR, et al. Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma. 2019;1–12. DOI:10.1080/02770903.2019.1630641.
   Web of Science ®Google Scholar
• Koenker R, Hallock KF. Quantile regression. J Econ Perspect. 2001;15(4):143–156..
   Web of Science ®Google Scholar
• Lê Cook B, Manning WG. Thinking beyond the mean: a practical guide for using quantile regression methods for health services research. Shanghai Arch Psychiatry. 2013;25(1):55–59. PubMed PMID: 24948867; eng..
   PubMedGoogle Scholar
• Sautner J, Andel I, Rintelen B, et al. Development of the M-SACRAH, a modified, shortened version of SACRAH (score for the assessment and quantification of chronic rheumatoid affections of the hands). Rheumatology. 2004;43(11):1409–1413.
   PubMed Web of Science ®Google Scholar
• Martin JA, Ramsay J, Hughes C, et al. Age and grip strength predict hand dexterity in adults. PloS One. 2015;10(2):e0117598.
   PubMed Web of Science ®Google Scholar
• Cerella J. Information processing rates in the elderly. Psychol Bull. 1985;98(1):67–83.
   PubMed Web of Science ®Google Scholar
• Montoye HJ, Lamphiear DE. Recreation. Grip and arm strength in males and females, age 10 to 69. Res Q. 1977;48(1):109–120.
   PubMed Web of Science ®Google Scholar
• Haward BM, Griffin MJ. Repeatability of grip strength and dexterity tests and the effects of age and gender. Int Arch Occup Environ Health. 2002;75(1–2):111–119.
   PubMed Web of Science ®Google Scholar
• Bellamy N, Sothern RB, Campbell J, et al. Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: relation between discomfort and disability. Ann Rheum Dis. 1991;50(4):243–248.
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014 Oct;16(10):971–976. PubMed PMID: 24720741; eng.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. PubMed PMID: 25007392.
   PubMed Web of Science ®Google Scholar
• Novartis. Full prescribing information: COSENTYX® (secukinumab) injection, for subcutaneous use; 2018.
   Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. PubMed PMID: 27959607..
   PubMed Web of Science ®Google Scholar
• Janssen. Full prescribing information: STELARA® (ustekinumab) injection, for subcutaneous or intravenous use revised 10/2017 ed. Horsham, PA: Janssen Pharmaceutical Companies; 2016.
   Google Scholar
• Azouz W, Chetcuti P, Hosker H, et al. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax(R) and Turbuhaler(R) devices: a randomised, cross-over study. BMC Pulm Med. 2015 May;1(15):47. PubMed PMID: 25927483; PubMed Central PMCID: PMCPMC4450517. eng..
   PubMed Web of Science ®Google Scholar
• D’Arcy S, MacHale E, Seheult J, et al. A method to assess adherence in inhaler use through analysis of acoustic recordings of inhaler events. PloS One. 2014;9(6):e98701. PubMed PMID: 24905012; PubMed Central PMCID: PMCPMC4048229. eng.
   PubMed Web of Science ®Google Scholar
• Holmes MS, Seheult JN, Geraghty C, et al. A method of estimating inspiratory flow rate and volume from an inhaler using acoustic measurements. Physiol Meas. 2013;34(8):903.
   PubMed Web of Science ®Google Scholar
• Taylor TE, Holmes MS, Sulaiman I, et al. Monitoring inhaler inhalations using an acoustic sensor proximal to inhaler devices. J Aerosol Med Pulm Drug Deliv. 2016 Oct;29(5):439–446. PubMed PMID: 26859629; eng.
   PubMed Web of Science ®Google Scholar
• Taylor TE, Zigel Y, Egan C, et al. Objective assessment of patient inhaler user technique using an audio-based classification approach. Sci Rep. 2018 Feb 01;8(1):2164.
   PubMedGoogle Scholar
• Glenn M, Kate Van B, Alan GZ, et al. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9(5):1071–1079. PubMed PMID: 25901022.
   PubMedGoogle Scholar
• Limmroth V, Gerbershagen K. Single-use autoinjector for once-weekly intramuscular injection of IFNbeta-1a. Expert Opin Drug Deliv. 2014 Dec;11(12):1969–1978. PubMed PMID: 25255732.
   PubMed Web of Science ®Google Scholar
• Seddighzadeh A, Hung S, Selmaj K, et al. Single-use autoinjector for peginterferon-beta1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the phase IIIb ATTAIN study. Expert Opin Drug Deliv. 2014 Nov;11(11):1713–1720. PubMed PMID: 25073663.
   PubMed Web of Science ®Google Scholar
• Pachon JA, Kivitz AJ, Heuer KU, et al. Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis. SAGE Open Med. 2014;2:2050312114564241. PubMed PMID: 26770759; PubMed Central PMCID: PMC4712753.
   Google Scholar
• Torjman MC, Machnicki R, Lessin J, et al. Evaluation of an investigational wearable injector in healthy human volunteers. Expert Opin Drug Deliv. 2017 Jan;14(1):7–13. PubMed PMID: 27809609; eng.
   PubMed Web of Science ®Google Scholar
• Patel J, Rainess RA, Benfield MJ, et al. Retrospective analysis of clinical outcomes associated with the use of pegfilgrastim on-body injector in patients receiving chemotherapy requiring granulocyte colony-stimulating factor support.0 (0):0018578719867659. Hosp Phar. 2019. DOI: 10.1177/0018578719867659.
   Google Scholar